(budesonide/formoterol fumarate dihydrate, inhalation powder)

A dry powder inhaler for the treatment of Asthma and COPD¹

  • Bioequivalent to Symbicort® Turbohaler®* with lower acquisition costs¹˒²˒³˒⁴

    (Based on 80-125% bioequivalence limits for AUC, Cmax, and standard flow parameters)

  • Patient friendly device with multiple feedback mechanisms, with a lower carbon footprint than pMDIs (in line with NHS carbon reduction strategy)⁶˒⁷
WockAIR Icon


WockAIR® is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:¹

WockAIR information


WockAIR® is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) <70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy¹

Adverse events should be reported. Reporting forms and information can be found at:

Adverse events should also be reported to Wockhardt UK. Please contact us or email us at


1. WockAIR® SmPC
2. Symbicort Turbohaler SmPC
3. Wockhardt Data on File
4. British National Formulary accessed August 2021
5. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2021. Available from Accessed February 2024

*Symbicort and Turbohaler are registered trademarks of the AstraZeneca AB

6. Virchow JC, Weuthen T, Harmer QJ, Jones S. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study. Expert Opin Drug Deliv. 2014;11(12):1849–57.
7. Janson C, et al. Thorax 2020;75:82–84. doi:10.1136/thoraxjnl-2019-213744. Carbon footprint impact of the choice of inhalers for asthma and COPD.